Anlon Healthcare Ltd.
AHCLNSEHealthcarePharmaceuticals & DrugsSmall Cap
₹16.3
▲ 3.49%
loading…
53
Composite
The company is a chemical manufacturing company engaged in manufacturing of pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs), which are supplied to customers both in India and international markets. Its products span across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API. It is also engaged in custom API development, including the preparation and submission of regulatory Drug Master Files (DMFs) for Indian and global markets.
Q-DITS fundamental score
53Composite
Growth
67
Profitability
84
Valuation
23
Quality
77
Solvency
60
Earnings
0
Key metrics
MCap
₹866 Cr
TTM PE
30.4x
Industry PE
38.2x
TTM EPS
₹0.54
Book Value
—
Face Value
₹2
Div Yield
0%
PEG
—
PB
0x
ROE
40.4%
ROCE
24.8%
EBITDA mgn
27.2%
D/E
0.83
Int. Cover
7.6x
Curr. Ratio
2.64x
EPS
₹0.51
Growth — CAGR across horizons
| Metric | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|
| Net Sales | 43% | — | — | — |
| EBITDA | 47.5% | — | — | — |
| Net Profit | 39% | — | — | — |
Score snapshot
Piotroski
6/9
Altman Z
1.74
Quality
77.2
Growth
66.7
Valuation
23
Earn. Qual
0
PEAD
0
SURGE
0
Loading price data…
Loading delivery data…
Revenue, profitability & returns
Revenue & Net Profit (₹ Cr)
RevenueNet Profit
Margins (%)
EBITDA%PAT%
Return ratios (%)
ROEROCEROA
Annual financials — last 4 years
Tap a row to expand the full chart
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| ›RevenueCr | 57 | 113 | 67 | 120 | |
| ›EBITDACr | 6 | 13 | 16 | 33 | |
| ›EBITDA margin | 10.4% | 11.3% | 23.8% | 27.2% | |
| ›Net profitCr | -0 | 6 | 10 | 21 | |
| ›PAT margin | -0.2% | 5.2% | 14.5% | 17.1% | |
| ›EPS₹ | ₹-0.01 | ₹0.48 | ₹0.6 | ₹0.51 | |
| ›Revenue growth | 0% | 97.5% | -41% | 80.7% | |
| ›PAT growth | 0% | 5,503.9% | 65.9% | 112.5% | |
| ›ROE | -6.9% | 130.4% | 68% | 40.4% | |
| ›ROCE | 6.4% | 15.4% | 15.5% | 24.8% | |
| ›ROA | -0.1% | 5.9% | 8.1% | 13.3% | |
| ›P/E | 0x | 0x | 0x | 0x | |
| ›P/B | 0x | 0x | 0x | 0x | |
| ›D/E | 40.1 | 9.5 | 3.9 | 0.8 | |
| ›Current ratio | 2x | 2x | 2x | 2.6x | |
| ›Interest cover | 1x | 2.8x | 3.3x | 7.6x |
Quarterly results
Tap a row to expand the full chart
| Metric | Trend | 2025-03 | 2026-03 |
|---|---|---|---|
| ›RevenueCr | 49 | 51 | |
| ›Rev growth YoY | — | — | 4% |
| ›EBITDACr | 17 | 15 | |
| ›EBITDA margin | 35.1% | 30% | |
| ›Net profitCr | 17 | 11 | |
| ›PAT growth YoY | — | — | -33.5% |
| ›EPS₹ | ₹4.18 | ₹1.98 |
Balance sheet — last 5 years (₹ Cr)
Tap a row to expand the full chart
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| ›Shareholders' equityCr | 2 | 7 | 21 | 80 | 210 | |
| ›ReservesCr | -10 | -5 | 5 | 41 | 157 | |
| ›Total borrowingsCr | 0 | 0 | 0 | 0 | 0 | |
| ›InvestmentsCr | 2 | 4 | 1 | 1 | 0 | |
| ›Total assetsCr | 54 | 66 | 76 | 119 | 317 | |
| ›Current assetsCr | 58 | 86 | 101 | 158 | 260 | |
| ›Current liabilitiesCr | 29 | 44 | 50 | 60 | 101 | |
| ›Trade payablesCr | 15 | 25 | 20 | 20 | 39 | |
| ›Gross blockCr | 35 | 35 | 38 | 36 | 40 |
Cash flow statement (₹ Cr)
Tap a row to expand the full chart
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| ›Operating CF (CFO)Cr | -2 | -3 | -3 | -23 | -46 | |
| ›Investing CF (CFI)Cr | -0 | -0 | -3 | 3 | -28 | |
| ›Financing CF (CFF)Cr | 3 | 2 | 8 | 19 | 76 | |
| ›Net cash changeCr | 1 | -1 | 2 | -1 | 2 | |
| ›Closing cashCr | 2 | 1 | 2 | 1 | 3 |
Cash flow components
CFO · CFI · CFF (₹ Cr)
CFOCFICFF
Q-DITS scorecard
Composite score
53
Quality (25%)77.2
Growth (25%)66.7
Valuation (20%)23
Piotroski (15%)67
Earnings Quality (10%)0
Momentum (5%)—
Weighted blend, rescaled to the components available for this stock.
Piotroski F-Score
6/9
✓ROA positiveROA 13.27%
✗CFO positiveCFO ₹-46.36 Cr
✓ROA improving8.06% → 13.27%
✗CFO > PAT (low accruals)CFO -46.36 vs PAT 20.52
✓Leverage decreasedD/E 3.86 → 0.83
✓Liquidity improvedCR 2.01 → 2.64
✗No share dilutionEPS 0.6 → 0.51
✓Margin improvedEBITDA mgn 23.75% → 27.2%
✓Asset turnover upAsset TO 0.56 → 0.78
Altman Z-Scoregrey
1.74
X1
0.501
X2
0.494
X3
0.098
X4
0.661
X5
0.379
>2.9 safe · 1.23–2.9 grey · <1.23 distress
Quality
77.2/100
ROE
40.4%
ROCE
24.8%
Margin
17.1%
Debt
0.8
Int. cover
7.6x
Growth
66.7/100
Revenue 3Y
43%
Profit 3Y
39%
EPS
-14.7%
Valuation
23/100
PE
0x
PB
0x
EV/EBITDA
2x
vs universe median: PE 25.6x · PB 2.81x · EV 13.41x
Earnings quality
0/100
CFO₹-46 Cr
PAT₹21 Cr
Accrual ratio0.211
CFO/PAT-2.26x
PEAD · SURGE
0 / 0
Revenue SUE—
EPS SUE—
Latest quarter2026-03
Rev growth YoY4%
Documents & filings
Loading documents…
Peer comparison
| Company | MCap (Cr) | Revenue | PAT | PE | PB | ROE% | ROCE% | D/E |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,40,794 | 58,462 | 11,565 | 38.4x | 5.3x | 16.2 | 19.9 | 0.03 |
| Divi's Laboratories Ltd. | 1,78,956 | 10,560 | 2,568 | 69.7x | 10.7x | 15.4 | 20.5 | 0 |
| Torrent Pharmaceuticals Ltd. | 1,49,820 | 13,980 | 2,138 | 69.3x | 17.9x | 26.8 | 19.3 | 1.76 |
| Cipla Ltd. | 1,09,370 | 28,163 | 3,870 | 28.2x | 3.2x | 11.8 | 16 | 0.01 |
| Lupin Ltd. | 1,07,537 | 27,958 | 5,355 | 20.2x | 4.8x | 21.1 | 22 | 0.3 |
| Zydus Lifesciences Ltd. | 1,06,823 | 27,148 | 5,026 | 21.2x | 4x | 21.1 | 26.1 | 0.13 |
| Dr. Reddy's Laboratories Ltd. | 1,06,133 | 33,700 | 4,144 | 25.3x | 2.8x | 18.6 | 23.3 | 0.14 |